NASDAQ
0.80USD
+0.01 (+1.29%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.1M
P/E
—
EPS
—
Beta
0.49
52W range
0.62-8.81
Day range
0.78–0.86
Open
0.80
Prev close
0.79
Volume
48K
Avg volume
78.4K
Dividend
0.00
IPO
2015-06-23
https://www.prnewswire.com/news-releases/aixcrypto-announces-second-quarter-2026-earnings-conference-call-details-302843169.html · 8/5/2026+0.00
https://www.prnewswire.com/news-releases/aixcrypto-debuts-at-automate-2026-unveiling-its-eai--web3-robot-ecosystem-strategy-with-the-launch-of-roboshare-and-aixc01-302807079.html · 6/23/2026+1.00
https://www.prnewswire.com/news-releases/aixcryptos-designated-investor-and-faraday-future-complete-amendment-to-12-million-investment-agreementexploring-rwa-related-applications-and-integration-of-real-world-assets-with-blockchain-infrastructure-302746330.html · 4/17/2026+0.60
https://www.prnewswire.com/news-releases/aixcrypto-co-ceo-jerry-wang-shares-weekly-investor-update-rwa-exploration-ecosystem-development-and-external-engagement-302741320.html · 4/14/2026
https://www.prnewswire.com/news-releases/aixcrypto-acknowledges-conclusion-of-sec-investigation-with-no-enforcement-action-involving-majority-controlling-stockholder-faraday-future-and-reaffirms-strategic-focus-302721716.html · 3/23/2026+0.80
https://www.prnewswire.com/news-releases/aixcrypto-inc-surpasses-1-1-million-registered-wallets-as-aixc-hub-launches-tenki-interactive-game-302673102.html · 1/28/2026+1.00
https://www.prnewswire.com/news-releases/aixcrypto-co-ceo-jerry-wang-shares-weekly-investor-update-crypto-flywheel-growth-302670584.html · 1/27/2026+0.80
https://www.prnewswire.com/news-releases/yt-jia-chief-advisor-to-aixc-shares-weekly-aixc-investor-update-aixc-appointed-andrew-grossman-as-head-of-legal-where-he-will-take-full-responsibility-for-the-companys-legal-compliance-and-governance-framework-302641869.html · 12/15/2025+0.80
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
